307 related articles for article (PubMed ID: 11160775)
1. Prevention of uremic bone disease using calcimimetic compounds.
Olgaard K; Lewin E
Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
[TBL] [Abstract][Full Text] [Related]
4. Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro.
Almaden Y; Rodriguez-Ortiz ME; Canalejo A; Cañadillas S; Canalejo R; Martin D; Aguilera-Tejero E; Rodríguez M
J Nephrol; 2009; 22(2):281-8. PubMed ID: 19384847
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
Nagano N
Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
[TBL] [Abstract][Full Text] [Related]
6. [Calcimimetic agents in the treatment of hyperparathyroidism secondary to chronic renal failure].
Negri AL; Slatopolsky EA
Medicina (B Aires); 2003; 63(2):165-71. PubMed ID: 12793088
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
[TBL] [Abstract][Full Text] [Related]
8. [Calcimimmetic and calcilytics: new perspectives of correction of abnormal parathormone (PTH) secretion].
Rybczyńska A; Hoppe A
Przegl Lek; 2003; 60(6):418-24. PubMed ID: 14974181
[TBL] [Abstract][Full Text] [Related]
9. [Calcimimetics, mechanisms of action and therapeutic applications].
Ureña P; Legoupil N; de Vernejoul MC
Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
[TBL] [Abstract][Full Text] [Related]
10. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism.
Fox J; Lowe SH; Conklin RL; Nemeth EF
Endocrine; 1999 Apr; 10(2):97-103. PubMed ID: 10451217
[TBL] [Abstract][Full Text] [Related]
11. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
Nagano N; Nemeth EF
J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
[TBL] [Abstract][Full Text] [Related]
12. Calcimimetics and hyperparathyroidism.
Krebs LJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
[TBL] [Abstract][Full Text] [Related]
13. Calcimimetics with potent and selective activity on the parathyroid calcium receptor.
Nemeth EF; Steffey ME; Hammerland LG; Hung BC; Van Wagenen BC; DelMar EG; Balandrin MF
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):4040-5. PubMed ID: 9520489
[TBL] [Abstract][Full Text] [Related]
14. Future role of calcimimetics in end-stage renal disease.
Goodman WG; Turner SA
Adv Ren Replace Ther; 2002 Jul; 9(3):200-8. PubMed ID: 12203202
[TBL] [Abstract][Full Text] [Related]
15. [Calcimimetics--a new treatment for hyperparathyroidism?].
Piecha G; Chudek J; Wiecek A
Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
[TBL] [Abstract][Full Text] [Related]
16. Calcimimetic agents: review and perspectives.
Ureña P; Frazão JM
Kidney Int Suppl; 2003 Jun; (85):S91-6. PubMed ID: 12753275
[TBL] [Abstract][Full Text] [Related]
17. The calcium receptor and calcimimetics.
Wada M; Nagano N; Nemeth EF
Curr Opin Nephrol Hypertens; 1999 Jul; 8(4):429-33. PubMed ID: 10491737
[TBL] [Abstract][Full Text] [Related]
18. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
Lindberg JS
Kidney Int Suppl; 2005 Jun; (95):S33-6. PubMed ID: 15882311
[TBL] [Abstract][Full Text] [Related]
19. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication.
Antonsen JE; Sherrard DJ; Andress DL
Kidney Int; 1998 Jan; 53(1):223-7. PubMed ID: 9453023
[TBL] [Abstract][Full Text] [Related]
20. Calcium-sensing receptor and calcimimetic agents.
Coburn JW; Elangovan L; Goodman WG; Frazaõ JM
Kidney Int Suppl; 1999 Dec; 73():S52-8. PubMed ID: 10633465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
